US 12208109

I'll run targeted searches for this exact patent number, including any 2026 CAFC docket activity.

Let me check for any 2026 litigation/appeal activity specifically naming this patent, and for a PTAB/CAFC docket.

US Patent 12,208,109 — Concise Summary

Important framing note: This number is a patent number (US 12,208,109 B2), not a docket. I searched USPTO-derived sources (Google Patents/PTAB, Orange Book aggregators) and Federal Circuit/CAFC 2026 material. I found no CAFC 2026 docket or appeal specifically naming patent 12,208,109, and I am flagging that as an explicit limitation rather than inferring one. The litigation and PTAB activity I located in the Helsinn/fosnetupitant space concerns other patent numbers (see "Litigation / docket status" below).

---

Bibliographic data

Sources: Google Patents (https://patents.google.com/patent/US12208109) and HT Syndication/ USPTO issuance notice (https://www.htsyndication.com/us-fed-news/article/us-patent-issued-to-helsinn-healthcare-on-jan.-28-for--physiologically-balanced-injectable-formulations-of-fosnetupitant---italian-inventors-/22213061782); DrugPatentWatch (https://www.drugpatentwatch.com/p/patent/12208109).

Abstract (as printed)

"Injectable dosages and formulations of fosnetupitant and pharmaceutically acceptable salts thereof are provided that are efficacious, chemically stable and physiologically balanced for safety and efficacy."

The specification expands this to a balanced fosnetupitant/netupitant ratio concept (95–99.99 : 0.01–5 weight parts), pH 7–10, avoidance of surfactants such as polysorbate 80/Tween 80, and disodium edetate as a hydrolytic-conversion inhibitor.

Plain-language overview of the independent claims

Claim 1 — Liquid IV formulation. A pharmaceutically stable intravenous liquid formulation whose active ingredient component consists essentially of the chloride hydrochloride salt of fosnetupitant at 2.3–30 mg/mL, plus (b) an alkalizing agent, and (c) an alkaline pH. Excipients such as EDTA, mannitol, and even palonosetron sit outside the "active ingredient component," which is why later dependent claims can add them without departing from "consisting essentially of."

Claim 2 — Lyophilized (freeze-dried) IV formulation. The same three elements — the fosnetupitant chloride hydrochloride active component at 2.3–30 mg/mL as measured on a suitable reconstitution volume basis, an alkalizing agent, and an alkaline pH.

Claim 22 — Method of manufacture. A method of making a liquid or lyophilized IV formulation consisting of fosnetupitant as the active ingredient, comprising: (a) admixing fosnetupitant or a pharmaceutically acceptable salt with sodium hydroxide in water at a basic pH to form a solution; (b) then reducing the pH back down to a basic pH (i.e., still above neutral) by adding one or more acidic pH-adjusting agents; and (c) then admixing with one or more pharmaceutically acceptable excipients. Claim 23 limits the acidic pH-adjusting agent to hydrochloric acid.

Dependent-claim themes (for context)

• pH: 7.5–10.0 (claims 3, 4, 12, 13); preferred 8.5–9.5 (claims 9, 19).
• Specific concentration: ~13.0 mg/mL chloride hydrochloride salt of fosnetupitant (claims 5, 9, 14, 19).
• Excipient package: sodium hydroxide (alkalizing), disodium edetate (chelator, 0.05–2.0 mg/mL, or 0.1–0.9 mg/mL), mannitol (bulking/tonicity, 10–100 mg/mL; ~38 mg/mL preferred), water q.s.
• Negative limitation: claims 10 and 20 recite the formulation "in the absence of a phosphate."
• Balanced-ratio limitation: claims 11 and 21 recite netupitant : fosnetupitant weight ratio 0.01:99.99 to 2:98.
• Claim-drafting oddity (not auto-corrected): claims 18 and 19 recite "sodium chloride and hydrochloric acid q.s. to pH 7.5–10.0 / 8.5–9.5" in the lyophilized claims, whereas the corresponding liquid claim 8 (and the specification) refers to sodium hydroxide. I am reporting the claim text literally; this may be a typographical artifact in the granted text.

Litigation / docket status (with caveats)

• The surfacing source marked "Family has litigation" points to a worldwide litigation dataset (Darts-ip family 59055193), i.e., general family-level litigation tracking rather than a specific US docket for this patent.
• The related Helsinn v. Gland Pharma Hatch-Waxman case (D.N.J., Civ. No. 22-4635) asserted U.S. Patents 8,426,450; 8,895,586; 9,186,357; 9,403,772; 9,908,907; 10,208,073; 10,624,911; 10,717,721; 10,828,297; and 11,312,698 — i.e., the earlier family members, not 12,208,109 (which did not issue until January 2025). That case was resolved by a Consent Judgment and Dismissal Order (see https://paragraphfour.com/wp-content/uploads/2022/07/njdc22cv4635CJ.pdf and the counterclaims at https://storage.courtlistener.com/recap/gov.uscourts.njd.[499051](/patent/499051)/gov.uscourts.njd.499051.25.0.pdf).
• IPR2025-00945, Azurity Pharmaceuticals v. Helsinn Healthcare, is an instituted-challenge track involving Helsinn, but it names US 8,623,826 B2, a different patent (see https://www.docketalarm.com/cases/PTAB/IPR2025-00945/).
• A June 2026 news item about a Delaware decision concerning Cinvanti reports invalidation/non-infringement findings against some Helsinn patents; that case does not name 12,208,109 as an asserted patent in the material I retrieved, and the source is a secondary news outlet, so treat it as low-confidence context only.

Bottom line on the docket question: I could not identify any 2026 CAFC (Federal Circuit) appeal, IPR, or district court docket in which 12,208,109 is itself the patent-in-suit. Given the patent's January 2025 issue date, any Paragraph IV certification or challenge directed to this number would necessarily post-date the Gland consent judgment. I do not have authoritative 2026 docket data confirming or denying such a case, and I am expressly not fabricating one.

I'll search for litigation involving US 12208109 specifically.

Let me search more targeted litigation databases.

Let me search more specifically for recent 2025–2026 litigation and PTAB activity.

Bottom line

I found no litigation specifically involving U.S. Patent No. 12,208,109. Searching litigation-oriented sources (CourtListener/recap, DrugPatentWatch litigation tables, PTAB/uspto PTACTS, firm and industry trackers), every hit for the number "12208109" outside the patent itself was a false positive — a UK Gazette company number, a Brazilian court document number, a Ukrainian administrative-offense case number, a Texas appellate cause number, and so on. None is a patent case.

I want to be explicit about the limits of that negative: I could not directly query PACER or the Unified Patents litigation caselist (the search tool available to me returned only web-indexed material), and U.S. district court complaints asserting a patent issued January 28, 2025 may not yet be well indexed on the open web. So treat "no litigation found" as not found in the sources searched, not as a certified universal negative.

---

Why the confusion risk is high here — and how I handled it

Per your instruction, I am interpreting every identifier literally and not auto-correcting. That matters, because two different patents are repeatedly conflated in the sources:

US 12,208,109 and US 10,624,911 share a title, inventors, assignee (Helsinn Healthcare SA), and priority date (June 6, 2016) — they are in the same family (Google Patents family ID 59055193). US 12,208,109 is a continuation of US 16/817,683 (US 11,529,362), which is a continuation of US 15/611,785 (US 10,624,911). They are nonetheless separate patents with separate claim sets, and I am not treating a case against the '911 patent as a case against the '109 patent.

---

Litigation in the same patent family (not against 12,208,109)

This is the closest thing that exists, and it is almost certainly what drives the "Family has litigation" flag on the Google Patents page for US 12,208,109 (https://patents.google.com/patent/US12208109/en, Darts-ip family 59055193).

Helsinn Healthcare S.A. v. Gland Pharma Limited

• Plaintiff: Helsinn Healthcare S.A.
• Defendant: Gland Pharma Limited
• Jurisdiction: U.S. District Court for the District of New Jersey
• Case No.: 2:22-cv-04635
• Filed: July 18, 2022
• Cause: 35 U.S.C. § 271 patent infringement (ANDA / Hatch-Waxman, NDA No. 210493, Akynzeo®)
• Accused product: Gland's ANDA No. 217374 — EQ 11.75 mg/mL fosnetupitant chloride hydrochloride and 0.0125 mg/mL palonosetron hydrochloride, 235 mg/0.25 mg per 20 mL single-dose vials for IV administration
• Patents asserted: '450, '586, '357, '772, '907, '073, '911, '721, '297, '698 (i.e., US 8,426,450; 8,895,586; 9,186,357; 9,403,772; 9,908,907; 10,208,073; 10,624,911; 10,717,721; 10,828,297; 11,312,698). Note the '911 patent here is US 10,624,911, not US 12,208,109 — and no patent numbered 12,208,109 appears in the list.
• Status: Gland answered and counterclaimed for declaratory judgments of non-infringement and invalidity (CourtListener recap, D.N.J. docket 499051, Docs. 25 and 31: https://storage.courtlistener.com/recap/gov.uscourts.njd.499051/gov.uscourts.njd.499051.25.0.pdf). DrugPatentWatch's Akynzeo litigation table shows a 2022-07-18 filing date with a 2022-12-23 termination date on at least one patent row (https://www.drugpatentwatch.com/p/litigation/drugname/index.php?query=AKYNZEO); I could not confirm from the indexed material whether that reflects dismissal, refiling, or a table artifact, so I am not representing a final outcome for this case.

Timing point that forecloses the obvious inference: US 12,208,109 was filed on November 15, 2022 and issued on January 28, 2025. It did not exist when Helsinn v. Gland was filed (July 18, 2022) and did not exist during Gland's Paragraph IV notice letters (June 2 and July 11, 2022). It therefore could not have been asserted in that case.

---

PTAB proceedings (family, not 12,208,109)

Azurity Pharmaceuticals, Inc. filed IPR petitions on May 1, 2025 against US 10,828,297, US 8,623,826, US 9,943,515, and US 9,186,357; per greyb/pharsight trackers, trial was instituted on November 19, 2025 for those four. No IPR or other PTAB proceeding naming US 12,208,109 appeared in the indexed results. (Sources: https://www.drugpatentwatch.com/p/litigation/drugname/index.php?query=AKYNZEO; https://pharsight.greyb.com/drug/akynzeo)

---

Practical significance / why litigation may yet appear

US 12,208,109 is listed as an Orange Book patent covering Akynzeo (see listings at https://pharsight.greyb.com/ingredient/fosnetupitant-chloride-hydrochloride;-palonosetron-hydrochloride-patent-expiration, which shows US 12,208,109 among the patents protecting Akynzeo, expiry listed June 2, 2037; also https://www.drugpatentwatch.com/p/patent/10624911 for the family). Because it is listed, any ANDA filer seeking a fosnetupitant/palonosetron IV generic must address it, and Helsinn would have a 45-day window to sue on Paragraph IV certification. Given the patent is roughly a year old at your stated date, future or recently filed but not-yet-indexed suits naming it are plausible. I cannot confirm any.

I also want to flag one widely cited Helsinn case that is not relevant here despite the name overlap: Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., 139 S. Ct. 628 (2019), the on-sale-bar / AIA § 102(a) case, concerned the palonosetron patent US 8,598,219 — not fosnetupitant and not US 12,208,109.

---

What I would do to close the gap

1. Query PACER directly for the District of New Jersey (and D. Del., N.D. Ill., S.D.N.Y. — common Hatch-Waxman venues) for civil actions filed after 2025-01-28 referencing "12,208,109."
2. Check the Unified Patents litigation caselist (https://portal.unifiedpatents.com/litigation/caselist) and Docket Alarm/Lex Machina by patent number rather than party name.
3. Run a CAFC docket search (the CAFC site indexes appeals by patent number) and a PTAB search restricted to the patent number.
4. Check the FDA Orange Book patent listing history for NDA 210493 to see the date US 12,208,109 was added, which bounds when a Paragraph IV certification against it could first have been sent.

If you can run those four against live databases, you will get a definitive answer; I have given you what the open web supports, and the honest answer is: no litigation against US 12,208,109 identified, with only family-level litigation (Helsinn v. Gland, D.N.J. 2:22-cv-04635) and family-level IPRs (Azurity, 2025) confirmed.

I'll verify the structured "no PTAB activity" signal against live sources before writing anything up.

The structured block says zero proceedings, but search surfaced an Azurity/Helsinn IPR cluster. I need to check whether any of those target the '109 patent specifically.

No IPR targets '109 so far. Let me run final confirmation searches — one on the patent number itself, one on whether it's been asserted in litigation (the usual trigger for an IPR).

PTAB proceedings on file

Verification performed: The structured ODP block returns no AIA trial proceedings for US 12,208,109. I attempted to falsify that default with targeted web searches (patent-number searches, petitioner-side searches, and DrugPatentWatch / Docket Alarm / IPVerse PTAB trackers for the Helsinn fosnetupitant portfolio). No IPR, PGR, or CBM naming US 12,208,109 was found. I did find a large adjacent IPR cluster against other Helsinn patents in the same product family — flagged below so it isn't mistaken for activity on this patent.

---

Proceedings overview

Total count: 0. Zero AIA trial proceedings on US 12,208,109 — 0 active, 0 with claims invalidated, 0 with claims sustained, 0 settled, 0 institution denials. The bottom line for a defendant: there is no PTAB win to lean on and no § 315(e)(2) estoppel shielding this patent. All 23 claims are live, unadjudicated, and fully challengable — but that cuts both ways, because an IPR defense against '109 would have to be built from scratch.

---

Proceedings on US 12,208,109

None. There is nothing to report at proceeding granularity, and I will not invent proceeding numbers to fill the template.

• Type: n/a
• Filed: n/a
• Status: n/a — no petition has been filed against this patent as of the most recent indexed data
• Judge panel: n/a
• Petition grounds: n/a
• Institution decision: n/a
• Final Written Decision: n/a — no claim of US 12,208,109 has ever been canceled, confirmed, or even instituted upon
• Settlement / termination: n/a
• Appeal: n/a
• Defensive value: Neutral-to-unfavorable in the narrow sense — you cannot point to a canceled claim, but you also face no adverse FWD. Everything is open on both sides.

Caveat on completeness

The Azurity petitions below (filed 2025-05-01) are fully indexed in public trackers within weeks, so the indexing lag on this docket is short. I cannot rule out a petition filed within the last few weeks that no tracker has surfaced yet, but the absence of any '109 filing throughout 2025–2026 while the same petitioner was methodically working through the rest of the Akynzeo IV portfolio is a meaningful negative signal.

Adjacent proceedings — NOT on this patent (flagged to prevent mis-citation)

Azurity Pharmaceuticals, Inc. filed a coordinated five-petition assault on other Helsinn patents covering the same fosnetupitant/palonosetron IV franchise. None of these names US 12,208,109:

• Petitioner: Azurity Pharmaceuticals, Inc. (counsel: Windels Marx — Richard Torczon et al.)
• Patent Owner: Helsinn Healthcare S.A. (counsel: Paul Hastings — Eric Dittmann, Naveen Modi et al.)
• Panel (confirmed for IPR2025-00948 / -00949): Administrative Patent Judges Michael J. Fitzpatrick, Sheridan K. Snedden, and Christopher J. Paulraj
• Grounds (illustrative, IPR2025-00947 on the '357 patent): § 103 only, 49 of 133 claims challenged — claims 1, 5-10, 17-39, 43-51 — over Herrstedt in view of Bös, with Herrington, ALOXI label, Hargreaves, and Bonadeo as secondary references
• Discretionary denial: Helsinn filed a § 325(d)/Fintiv discretionary-denial request in all five; Acting Director Coke Morgan Stewart denied it on 2025-09-19 and referred the petitions to the Board, weighing Helsinn's settled expectations (patents in force since 2014–2020) against the absence of a parallel district court proceeding and Azurity's unrebutted attack on the examiner's Rule 132 synergy evidence
• Key procedural dates: institution decisions 2025-11-19; expert deposition of Dr. Stephen J. Peroutka taken 2026-01-13; Patent Owner Responses filed 2026-02-25. Statutory FWD deadline is approximately 2026-11-19 for each instituted case.
• Appeal: none — no FWD has issued on any of the five.
• Relevance to '109: These are the patents Helsinn asserted in the 2022 Gland ANDA litigation (D.N.J. 2:22-cv-04635). They are different statutory classes — method-of-treatment patents on netupitant/palonosetron combinations, not formulation patents on the chloride hydrochloride salt of fosnetupitant. A finding of unpatentability in any of them would not cancel or narrow any claim of '109.

Links: Docket Alarm IPR2025-00948 docket; Director referral decision, 2025-09-19; IPVerse IPR2025-00949 case page; US 12,208,109 on Google Patents; Gland counterclaims, D.N.J. 2:22-cv-04635.

---

Strategic summary

Claim status on US 12,208,109. All 23 claims — independent claims 1, 2, and 22, and dependent claims 3-21 and 23 — are UNTESTED. Nothing is canceled; nothing is sustained; nothing has been construed by the Board. The patent is a continuation (via US 11,529,362 and US 10,624,911, tracing to provisional US 62/345,942, priority 2016-06-06) that issued 2025-01-28 with an adjusted expiration listed as 2037-09-18 on Google Patents (third-party trackers list the Orange Book expiry as 2037-06-02). Because no petition has been instituted against it, the file contains no FWD, no Board claim construction, and no estoppel-producing event. If you are a defendant, note that the patent is the newest member of a family already under coordinated IPR attack — it is the most likely next target.

Estoppel landscape. This is the cleanest part of the picture for a defendant: no § 315(e)(2) estoppel attaches to US 12,208,109 at all. Azurity's five instituted IPRs produce estoppel as to the '826, '357, '515, and '297 patents only. Prior art that Azurity raised or reasonably could have raised in those cases is not your problem in an IPR on '109, because estoppel runs to the petitioner and its privies, not to unrelated defendants — and in any event none of those grounds were directed at the '109 claims. Practically, the full universe of § 102/§ 103 art against the '109 claims remains available. One asymmetry to exploit: the prosecution-favorable story Helsinn has been telling in the parallel IPRs — that the examiner allowed the family's claims on inventor Rule 132 evidence of synergy between netupitant and palonosetron in a method of treatment — has no counterpart in the '109 file, whose claims are directed to a formulation (fosnetupitant salt + alkalizing agent + alkaline pH), supported by stability/opalescence data. If Azurity wins or loses on the synergy narrative, it says little about the formulation claims.

Pattern signals. A single well-resourced petitioner (Azurity, backed by Windels Marx) has filed five coordinated IPRs against four Helsinn patents and separately pursued PGR2025-00035 against Heron Therapeutics on US 12,115,254 and an IPR against Exelixis on US 12,128,039 — this is a serial petitioner with an established ANDA/505(b)(2) litigation strategy, not a defensive aggregator. No Unified Patents involvement appears anywhere in this chain. Helsinn is a vigorous patent owner: it litigated the Gland ANDA in 2022, filed discretionary-denial requests in all five Azurity IPRs, and contested them on the merits with a substantial expert and objective-indicia record. The most important procedural signal for planning is the 2025-09-19 Director decision denying discretionary denial — post-Fintiv-rescission practice makes discretionary denial hard to obtain where there is no parallel district court proceeding and the petitioner credibly attacks the prosecution record.

---

Recommended next steps

If you are a defendant, there is no PTAB disposition to cite. Say so explicitly in your demand-letter response rather than implying one exists: no claim of US 12,208,109 has been canceled, and no FWD, institution decision, or settlement exists for this patent. Any assertion by an adversary that "'109 has already survived or fallen at the PTAB" is unsupported.

• PGR is likely foreclosed; IPR is the available vehicle. The '109 patent issued 2025-01-28. The § 321(c) nine-month PGR window closed on or about 2025-10-28 — before today (2026-09-28). IPR under §§ 311-319 is therefore the only path, and it limits you to § 102/§ 103 grounds on patents and printed publications. If you were contemplating § 112 written-description or enablement attacks on the formulation claims, those had to be brought in a PGR and that door has closed on the '109 patent.
• If you file, calendar the one-year clock. The Board's statutory deadline is one year from institution (extendable to 18 months for good cause under § 316(a)(11)). Track institution-decision deadlines from your filing date and note that the current Board is instituting at a high rate on this portfolio: all five Azurity petitions were instituted on 2025-11-19, roughly six and a half months after the 2025-05-01 filings.
• Build the art record against this patent specifically. Do not recycle the Herrstedt/Bös/Herrington ground structure from IPR2025-00945 through -00949 — those target method claims with a "synergy" prosecution history. The '109 claims recite a formulation: "an active ingredient component consisting essentially of from 2.3 to 30 mg/ml of the chloride hydrochloride salt of fosnetupitant," "an alkalizing agent," and "an alkaline pH." The relevant art is parenteral formulation art on the fosnetupitant salt and its stability/hydrolysis behavior (including WO 2013/082102, cited on the face of the patent and relied on in the specification for the 10 mg/mL disclosure), and the "consisting essentially of" transition in claims 1 and 2 is a claim-construction battleground worth developing early.
• Separately monitor the five Azurity IPRs with FWDs due on or about 2026-11-19. They will not cancel '109 claims, but a Board finding on the reliability of the family's Rule 132 synergy evidence bears on Helsinn's overall credibility trajectory and on how aggressively it can re-litigate the same inventor-declaration strategy.
• Watch for new activity. The absence of any IPR against '109 is itself a signal that the patent has not yet been asserted in an ANDA/505(b)(2) case that would trigger a petition. If Helsinn asserts '109 against a new filer, expect a petition within the § 315(b) one-year window. Monitor USPTO Patent Trial and Appeal Board End-to-End and CourtListener for a complaint naming the '109 patent.

Confidence note: My conclusion of "zero proceedings" rests on the structured ODP block (canonical) plus corroborating searches across PTAB trackers. It is high-confidence for filings through the most recent indexing cycle, but I have not independently confirmed a total absence of filings in the last few weeks, and I flag that residual gap rather than overstate the negative.

I'll reconstruct the assignment chain for US 12,208,109, starting with targeted searches for USPTO assignment records, the security-interest parties, and the corporate chain of Helsinn entities.

Let me dig into the security-interest counterparty, the Helsinn corporate chain, and any assignment-center records.

Assignment & Ownership Analysis — US 12,208,109 B2

Data-access caveat up front (read before the timeline): The authoritative source I was given — the full Google Patents record — surfaces this patent's post-filing legal events (conveyance type, parties, dates) but not reel/frame numbers or the correspondent of record. My attempts to pull the underlying USPTO Assignment Center entries (assignmentcenter.uspto.gov) for this number returned no accessible detail pages. I therefore report the two recorded conveyances that are documented, and I explicitly flag the reel/frame and correspondent fields as not retrieved rather than inventing them. This is an honesty limitation, not a finding that the records are absent.

---

Inventors

Employer note: Both inventors are named on multiple other Helsinn-owned filings in the same chemical family — e.g., US 10,208,073 (substituted 4-phenyl pyridines, "Helsinn Healthcare SA, Lugano/Pazzallo (CH)") and EP 2,785,706 — where they appear alongside a larger Helsinn R&D roster (Fadini, Manini, Pietra, Giuliano, Lovati, Stella). That co-inventor overlap and the shared Varese, Italy, address strongly indicate employment by the Helsinn group's Italian research operation. I could not confirm the exact signing entity (Helsinn Healthcare SA vs. an Italian affiliate) from an employment record, so I mark the precise employer as not directly confirmed.

Unusual-pattern check — not present / no signal. I found no evidence either inventor departed Helsinn within 12 months of filing, and no inventor-side assignment or departure is reflected in the patent's legal events. The two inventors also continue to appear on later Helsinn filings, which is the opposite of a pre-fire-sale exodus. No follow-on inventor assignments were found.

---

Original assignee

Helsinn Healthcare SA, Via Pian Scairolo 9, 6912 Lugano/Pazzallo, Switzerland.

• Entity type / business: Privately held Swiss pharmaceutical group, founded 1976 by Gabriele Braglia; third-generation family-owned (Riccardo Braglia, Executive Chairman/CEO; Gabriele Edoardo Braglia on the board). Primary business is in-licensing, developing, and out-licensing oncology/supportive-care pharmaceuticals — it is a licensor/marketer, not a pure R&D shell (Helsinn's own description: "worldwide licensor of palonosetron," "core business is the licensing of pharmaceuticals").
• Products embodying the claims — yes. The claims are Orange-Book-listed against AKYNZEO, NDA 210493, fosnetupitant chloride hydrochloride / palonosetron hydrochloride, in both dosage forms covered by the divisional family: IV powder (210493-001, approved Apr. 19, 2018) and IV solution (210493-002, approved May 27, 2020). Patent 12,208,109 is flagged as a "product" and "substance" patent for 210493-001 and a "product" patent for 210493-002. So the original assignee is undeniably an operating company that ships the claimed subject matter.
• Group structure: Operating subsidiaries Helsinn Therapeutics (U.S.), Inc. (Iselin, NJ) and Helsinn Birex Pharmaceuticals Ltd. (Dublin, Ireland — drug-product manufacturing). A Jan. 13, 2022 restructuring spun out HAS Healthcare Advanced Synthesis SA as an independent business.
• Current status: Operating, privately held, no bankruptcy, no dissolution, no acquisition found. Financials are not publicly disclosed by policy.

Cross-source discrepancy to flag: the GreyB/Slate aggregator page for US12208109B2 renders the assignee as "Helsinn Birex Pharmaceuticals Ltd", whereas the issued patent front page, Google Patents, and every other aggregator (DrugPatentWatch, GreyB Pharsight) list Helsinn Healthcare SA. The Birex label is almost certainly an artifact of the 2022 group-wide security agreement (below), in which Helsinn Birex was one of the pledging assignors. It should not be read as a genuine transfer of title to Birex.

---

Assignment timeline

The patent's Google Patents "Assigned to" legal events disclose the following recorded conveyances. Reel/frame and correspondent fields were not retrievable and are marked accordingly — I do not fill them with placeholders.

• 2016-06-06 — Priority established (provisional US 62/345,942); 2017-06-02 — US 15/611,785 filed by Helsinn Healthcare SA.

  • Conveyance: (initial) Assignment — presumed, standard practice, and consistent with the issued patent naming Helsinn Healthcare SA as assignee, but I could not retrieve the recording record, reel/frame, or correspondent.
  • Assignor: Alessio Venturini; Roberta Cannella
  • Assignee: Helsinn Healthcare SA
  • Correspondent: not retrieved
  • Context: acquisition — routine inventor-to-employer assignment made in the ordinary course at filing.

• 2022-12-30 (recorded) — Reel not retrieved

  • Conveyance: Security Interest ("see document for details")
  • Assignor group: Helsinn Birex Pharmaceuticals Limited; Helsinn Healthcare SA; Helsinn Therapeutics (U.S.), Inc.
  • Assignee: HAMILTON SA LLC
  • Correspondent: not retrieved
  • Context: securitization — a group-wide collateral grant by all three Helsinn operating entities to a secured party/agent (Hamilton SA LLC), i.e., the patent dynasty was pledged as loan/royalty-financing collateral. This was recorded ~6 weeks after the 2022-11-15 continuation filing, so it functions as a portfolio-wide encumbrance rather than a transfer of title.

• 2023-09-20 (recorded) — Reel not retrieved

  • Conveyance: Release by Secured Party ("see document for details")
  • Assignor: HAMILTON SA LLC
  • Assignee (title restored to): Helsinn Healthcare SA; Helsinn Therapeutics (U.S.), Inc.; Helsinn Birex Pharmaceuticals Limited
  • Correspondent: not retrieved
  • Context: securitization release — the security interest was discharged (financing repaid/refinanced and lien released), returning the portfolio unencumbered to the Helsinn entities. This is the mirror-image of the 2022-12-30 record, ~9 months later.

No other recorded assignments were found for this patent. In particular: no transfer to any "IP/Holdings/Ventures/Licensing" entity, no change of name, no merger, no license record, and no assignment to a defensive aggregator.

If a full Assignment Center pull reveals the inventor→Helsinn initial assignment plus its reel/frame, that would be the only missing link; the chain beyond it is fully accounted for by the two records above.

---

Timeline diagram

timeline
    title Ownership of US 12208109
    2016 : Priority filing by inventors
         : Presumed assignment to Helsinn
    2017 : US 15611785 filed by Helsinn Healthcare SA
    2022 : Security interest to Hamilton SA LLC
    2023 : Release by secured party
         : Title returns to Helsinn entities
    2025 : Patent issues to Helsinn Healthcare SA

---

NPE / troll-pattern signals

1. Shell-entity transfer — NOT PRESENT. No assignment moves title out of the operating group. The only third party in the chain is Hamilton SA LLC, which appears solely as a secured party (2022-12-30 security interest) that released its interest on 2023-09-20. A security interest is an encumbrance, not a conveyance of ownership, and it was extinguished. No "IP/Holdings/Ventures/Licensing" assignee appears.

2. Known asserter in the chain — NOT PRESENT. Neither Helsinn Healthcare SA, Helsinn Birex Pharmaceuticals Ltd., Helsinn Therapeutics (U.S.), Inc., nor Hamilton SA LLC matches any public NPE/asserter list (Acacia, Marathon, IV, IPNav, Wi-LAN/Conversant, Vringo, Pendrell, Round Rock, Spangenberg entities, etc.). All Helsinn entities are operating pharmaceutical companies; Hamilton SA LLC behaves as a lender/agent, not a litigant.

3. Repeat correspondent across the chain — UNCLEAR / NOT ASSESSABLE. The correspondent of record for the 2022 and 2023 recordings was not retrievable in my searches, so I cannot test for a recurring filing attorney. I decline to guess. (Note: if the inventor assignment shows the same correspondent as the security/release records, that would still point to routine Helsinn outside counsel — not an NPE "lawyer across the shells" pattern, since the assignees here are all operating entities.)

4. Cascading transfers — NOT PRESENT. Only two recordings exist, both parts of a single financing/refinancing (pledge then release), spanning ~9 months, between the same counterparties. There is no chain of successive LLCs.

5. Pre-litigation transfer — NOT PRESENT. No assignment precedes any suit naming this patent. As established in the prior section, the Helsinn v. Gland Pharma Hatch-Waxman action (D.N.J. 22-4635) asserted the earlier family members (e.g. '450, '586, '357, '772, '907, '073, '911, '721, '698), not 12,208,109, which did not issue until Jan. 28, 2025. No transfer into a litigation vehicle is visible.

6. Bankruptcy fire-sale — NOT PRESENT. No Chapter 7/11, no sale-of-assets proceeding; Helsinn is privately held, operating, and self-funds (it explicitly does not disclose financials). The 2022 security interest is a going-concern financing, not a liquidation.

7. Privateering — NOT PRESENT. There is no transfer to a third-party NPE to assert on Helsinn's behalf. Helsinn retains title and asserts its own family patents directly (the Gland suit was brought by Helsinn itself).

8. Defensive aggregator — NOT PRESENT. The chain does not terminate at RPX, AST, LOT, Unified, or OIN. It terminates at the original operating owner, Helsinn Healthcare SA.

---

Verdict

Operating-company assertion.

Justification: The only recorded conveyances touching US 12,208,109 are a group-wide security interest to Hamilton SA LLC (recorded 2022-12-30) and its release by secured party (recorded 2023-09-20) — a pledge and discharge that left title with the original operating group. The patent is owned by Helsinn Healthcare SA, which markets AKYNZEO (NDA 210493) — the very product the claims are Orange-Book-listed against — and which litigates its fosnetupitant family directly against ANDA filers (Helsinn v. Gland Pharma, D.N.J. 22-4635). No shell entity, known NPE, cascading LLC chain, or defensive aggregator appears anywhere in the record. Confidence note: because the reel/frame and correspondent fields could not be pulled from Assignment Center, the inventor-assignment link and the "repeat correspondent" test remain unverified; if a true Assignment Center record were to reveal an undisclosed transfer to a third-party asserter, this verdict would need revisiting — but nothing in the available record supports that.

Verify at: USPTO Assignment Center search — https://assignmentcenter.uspto.gov/ (search patent number 12208109) / https://assignment.uspto.gov/patent/index.html. Cross-referenced here against Google Patents legal events (https://patents.google.com/patent/US12208109/en) and the Helsinn v. Gland Pharma counterclaim record (https://storage.courtlistener.com/recap/gov.uscourts.njd.[499051](/patent/499051)/gov.uscourts.njd.499051.25.0.pdf).

I'll verify the USPTO record for 12,208,109 and pull details on each cited reference before building the anticipation analysis.

Now let me verify the remaining cited references and the patent's front-page citation list.

Prior Art Analysis — U.S. Patent No. 12,208,109 B2

Note on the record and tool limits. The authoritative text I was given is the full Google Patents record for US12208109B2, which mirrors USPTO bibliographic and legal-events data. I confirmed the number literally as 12,208,109 B2 (application 17/986,934; filed 2022-11-15; granted 2025-01-28; applicant Helsinn Healthcare SA; inventors Alessio Venturini and Roberta Cannella; priority 2016-06-06 via provisional 62/345,942). I did not substitute results for similar numbers, and I did not auto-correct any identifier. I could not directly query the USPTO's internal databases with the tools available (Google Patents + DrugPatentWatch were used as the mirror sources); where I rely on a secondary source I say so.

Headline finding up front (stated plainly rather than inferred): None of the eight patent references cited on the face of US 12,208,109 anticipates any of its 23 claims under 35 U.S.C. § 102. Every one of them fails the "all elements arranged as claimed in a single reference" test for independent claims 1, 2, and 22, and therefore cannot anticipate the dependents either. Details and the closest-call reasoning are below.

---

1. The § 102 framework applied

• Governing statute: AIA. The effective filing date is 2016-06-06, which post-dates 2013-03-16. AIA §§ 102/103 apply.
• All eight cited references are § 102(a)(1) art. Each was published or issued more than one year before 2016-06-06, making them "patented, described in a printed publication, or in public use… before the effective filing date." They are therefore also statutory-bar-type art in substance, and the grace-period/exception provisions of § 102(b)(2)(A)–(C) do not reach them (those exceptions apply to § 102(a)(2) art, i.e., U.S. patents and published applications, not to § 102(a)(1) printed publications).
• Consequence for the Helsinn common-owner references (WO2013082102, US8426450, US20060167072): common ownership does not remove them from the prior-art field, because they are § 102(a)(1) art, not § 102(a)(2) art. This is why the examiner was able to cite Helsinn's own WO 2013/082102 against the application.
• Anticipation standard: a single reference must disclose every claimed element, arranged as in the claim, so that a POSA could practice the claim without undue experimentation. Near-misses on one element defeat anticipation (they may support § 103, which is addressed in the prior Obviousness section and not repeated here).

The elements that must appear in a single reference for the independent claims:

Nothing in the cited set discloses element (b)+(c) together with the specific fosnetupitant salt at the recited concentration. That is the analytical bottleneck for every reference below.

---

2. Reference-by-reference analysis

2.1 — WO 2013/082102 A1 (Helsinn Healthcare SA) — the single most relevant cited reference

• Full citation: WO 2013/082102 A1, "Substituted 4-phenyl-pyridines for the treatment of NK-1 receptor related diseases," Helsinn Healthcare SA. PCT/US2012/066778.
• Dates: Priority 2011-11-29 (US 61/564,537) and 2012-05-23 (US 13/478,361); international filing 2012-11-28; publication 2013-06-06. (U.S. family equivalent: US 9,403,772; EP equivalent EP 2 785 706 B1.)
• Description: Genus and species disclosure of substituted 4-phenyl-pyridines as NK-1 antagonists, compositions containing them with pharmaceutically acceptable excipients, and methods of treating emesis incl. CINV/RINV/PONV. PubChem and the EP/ES family publications confirm it expressly names species GA1 = 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonoxy)methyl)piperazin-1-ium — i.e., fosnetupitant itself — plus pharmaceutically acceptable salts and forms in which the phosphonate bears "an organic or inorganic cation." It also discloses intravenous administration.
• § 102 availability: Yes — § 102(a)(1) (published 2013-06-06, three years before the critical date). Common ownership by Helsinn does not except it (see § 1 above).
• Anticipation analysis: This reference maps the active-ingredient element of claims 1 and 2 (fosnetupitant and its salts) and, per the applicant's own Background characterisation, discloses an IV concentration of "about 10 mg/mL … based on the weight of the active moiety," which converts to ~11.1–13.2 mg/mL of the chloride hydrochloride salt (MW 761.53 vs. free base 688.6; the patent's own ratio table is 1.106:1) — inside the claimed 2.3–30 mg/mL range. But it fails on two elements: (i) it does not disclose the specific "chloride hydrochloride" salt in the excerpt I retrieved (a factual gap I flag rather than assume), and (ii) it discloses no alkalizing agent and no alkaline pH for a fosnetupitant formulation. Under § 102, a reference that discloses a compound and a concentration but not the recited vehicle/pH does not anticipate a formulation claim.
• Claims it potentially anticipates: None. It is the closest cited art to claims 1, 2, 5, 14 (fosnetupitant species + ~10 mg/mL IV concentration) and, because it discloses netupitant as the active moiety, to claims 11 and 21, but it does not disclose a single formulation meeting any full claim.

2.2 — WO 2014/005606 A1 (Pharmathen S.A.)

• Full citation: WO 2014/005606 A1, "Stable injectable pharmaceutical composition of neurokinin 1 receptor antagonist and process for preparation thereof," Pharmathen S.A., EP 2012/002854.
• Dates: Priority/filing 2012-07-06; publication 2014-01-09. (U.S. equivalent US 2015/0165045 A1.)
• Description: Controlled-release sterile injectable (IM/SC) NK-1 antagonist formulations — aqueous ready-to-use solutions, non-aqueous suspensions, and sol-gels — containing aprepitant or fosaprepitant or a pharmaceutically acceptable salt/derivative/metabolite, e.g., fosaprepitant dimeglumine at 142.7 g/L, with viscosity-enhancing agents. Retrieved text states: "Sodium Phosphate and NaOH or HCl were used at appropriate amounts in order to adjust pH at 7," and the solutions showed "good syringability and injectability."
• § 102 availability: Yes — § 102(a)(1).
• Anticipation analysis: This teaches the pH-adjustment technique (NaOH/HCl) for a phosphono-prodrug NK-1 antagonist and the use of a base salt (dimeglumine) to solubilise that chemotype. But the active ingredient is fosaprepitant, not fosnetupitant — a structurally different molecule. A reference that does not disclose the claimed active ingredient cannot anticipate a claim drawn to that ingredient, no matter how close the formulation technique. It also titrates to pH 7, not to the claimed alkaline pH.
• Claims it potentially anticipates: None. Not one element (a) of any independent claim is met. Its relevance is purely § 103 (motivation/excipient technique).

2.3 — U.S. Patent No. 8,426,450 B1 (Helsinn Healthcare SA)

• Full citation: US 8,426,450 B1, "Substituted 4-phenyl pyridines having anti-emetic effect," Fadini et al., Helsinn Healthcare SA; application 13/478,361.
• Dates: Priority 2011-11-29; filed 2012-05-23; granted 2013-04-23.
• Description: Claims a 4-phenyl-pyridine compound (netupitant chemotype) and "a pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1, and one or more pharmaceutically acceptable excipients" (claim 2), plus a Markush group of compounds (claim 3). Its background discusses the University of Kansas N-phosphoryloxymethyl prodrug strategy (U.S. 5,985,856) as a known way to "improve the solubility profiles" of amines — the structural strategy embodied in fosnetupitant.
• § 102 availability: Yes — § 102(a)(1) (patented 2013-04-23).
• Anticipation analysis: At most it discloses NK-1 antagonist compounds and a genus-level composition ("one or more pharmaceutically acceptable excipients"). It does not disclose a 2.3–30 mg/mL fosnetupitant chloride hydrochloride solution, an alkalizing agent, or an alkaline pH. A generic excipient recitation is not a disclosure of the claimed alkalizing-agent/alkaline-pH combination, and inherency cannot be presumed where the reference does not require it.
• Claims it potentially anticipates: None. Closest to the active-ingredient element of claims 1 and 2; silent on all other elements.

2.4 — WO 1995/023798 A1 (Merck & Co., Inc.)

• Full citation: WO 1995/023798 A1, "Prodrugs of morpholine tachykinin receptor antagonists," Dorn, Hale, MacCoss, Mills; Merck & Co., Inc.
• Dates: Priority 1994-03-04; international filing 1995-02-28; publication 1995-09-08. (U.S. equivalent US 5,691,336; EP 0 748 320.)
• Description: Substituted morpholine heterocycles as tachykinin receptor antagonists useful for inflammatory disease, pain/migraine, asthma, and emesis; the disclosure is expressly framed around prodrug design — converting a parent NK-1 antagonist to a phosphate/phosphonate ester that hydrolyses in vivo to release the parent, with the stated advantage of "enhanced water solubility for parenteral administration."
• § 102 availability: Yes — § 102(a)(1) (published 1995-09-08).
• Anticipation analysis: Teaches the prodrug concept for NK-1 antagonists generally, and the solubility rationale for parenteral phospho-prodrugs. It discloses no fosnetupitant, no 4-phenyl-pyridine-piperazinium chemotype, no concentration, no alkalizing agent, and no alkaline-pH formulation. The chemical class is entirely different (morpholine vs. 4-phenyl-pyridine).
• Claims it potentially anticipates: None. § 103 background art only.

2.5 — WO 1995/018124 A1 (Merck Sharp & Dohme Limited)

• Full citation: WO 1995/018124 A1, "Substituted morpholine derivatives and their use as therapeutic agents," Baker et al.; Merck Sharp & Dohme Ltd.; PCT/GB94/02819.
• Dates: Priority 1993-12-29; publication 1995-07-06. (EP 0 777 659 B1 family.)
• Description: Morpholine derivatives bearing an amine-substituted azo-heterocyclic moiety, as tachykinin (NK-1) antagonists "of particular use in the treatment of pain, inflammation, migraine and emesis"; includes pharmaceutically acceptable salts and prodrugs thereof.
• § 102 availability: Yes — § 102(a)(1).
• Anticipation analysis: Discloses a different chemical genus, an anti-emetic utility, and generic salt/prodrug language. It discloses none of the claimed fosnetupitant salt, concentration, alkalizing agent, or alkaline pH.
• Claims it potentially anticipates: None.

2.6 — WO 1995/016679 A1 (Merck & Co., Inc.)

• Full citation: WO 1995/016679 A1, "Morpholine and thiomorpholine tachykinin receptor antagonists," Merck & Co., Inc.
• Dates: Priority 1993-12-17; publication 1995-06-22.
• Description: Morpholine/thiomorpholine NK-1 (tachykinin) receptor antagonists and their use in treating substance-P-mediated disorders, including emesis and CNS conditions. (This reference is also cited in the '109 specification in the substance-P passage discussing WO 95/16679, WO 95/18124 and WO 95/23798.)
• § 102 availability: Yes — § 102(a)(1).
• Anticipation analysis: Same as 2.4/2.5 — different chemical class, no fosnetupitant, no formulation parameters. Only the disease context overlaps.
• Claims it potentially anticipates: None.

2.7 — US 2006/0167072 A1 (Helsinn Healthcare SA)

• Full citation: US 2006/0167072 A1, "Liquid pharmaceutical formulations of palonosetron," Helsinn Healthcare SA.
• Dates: Priority 2004-01-30; publication 2006-07-27.
• Description: Liquid (injectable) palonosetron formulations — i.e., the excipient-platform art for the Aloxi® 5-HT3-antagonist solution: aqueous vehicle, mannitol as tonicity agent, disodium edetate as chelator/stabiliser, and pH adjustment with sodium hydroxide and hydrochloric acid.
• § 102 availability: Yes — § 102(a)(1).
• Anticipation analysis: This is the source of the "EDTA + mannitol + NaOH/HCl" excipient package, but it is directed to palonosetron, and — critically — no claim of US 12,208,109 recites palonosetron. It therefore cannot anticipate any claim. Its relevance is confined to the dependent excipient claims (6–9, 15–19) under § 103, not § 102.
• Claims it potentially anticipates: None.

2.8 — US 2010/0048607 A1 (Chandrashekhar Kocherlakota)

• Full citation: US 2010/0048607 A1, "Formulations comprising palonosetron," Kocherlakota.
• Dates: Priority 2008-08-25; publication 2010-02-25.
• Description: Third-party palonosetron formulation disclosures (liquid/stable palonosetron compositions and their excipient/pH handling).
• § 102 availability: Yes — § 102(a)(1).
• Anticipation analysis: Palonosetron-only. As with 2.7, because the '109 claims do not recite palonosetron, and this reference discloses no fosnetupitant salt, no 2.3–30 mg/mL fosnetupitant, and no alkaline-pH fosnetupitant vehicle, it cannot anticipate any claim.
• Claims it potentially anticipates: None.

---

3. Element-coverage matrix (why every § 102 theory fails)

No row shows all five/six elements. Anticipation requires a single row complete across all elements; none is.

---

4. Most relevant prior art (ranked)

Because § 102 fails across the board, "relevance" here is best understood as closeness of subject matter and usefulness as § 103 art:

1. WO 2013/082102 A1 (Helsinn) — most relevant. Only cited reference that discloses fosnetupitant itself, its salts, IV administration, and an IV concentration landing inside the claimed range. As noted in the prior Obviousness section, this is the primary reference against claims 1–5 and 12–14.
2. WO 2014/005606 A1 (Pharmathen) — teaches NaOH/HCl pH adjustment of an injectable phosphono-prodrug NK-1 antagonist and base-salt solubilisation; the natural secondary reference.
3. US 8,426,450 B1 (Helsinn) — NK-1 antagonist genus + prodrug-solubility rationale; supplies the "compound" element and the known-prodrug context.
4. US 2006/0167072 A1 and US 2010/0048607 A1 — excipient-platform art (mannitol, disodium edetate, NaOH/HCl), relevant only to the dependent excipient claims under § 103.
5. WO 95/16679, WO 95/18124, WO 95/23798 (Merck) — remote background; chemical class and prodrug concept only.

---

5. Honest caveats and open items

1. Two facts I could not confirm within my search budget, and which I therefore do not assert: (i) whether WO 2013/082102 discloses the chloride hydrochloride salt specifically (as opposed to salts and "organic or inorganic cations" generally); and (ii) whether WO 2013/082102 contains a worked IV formulation example with a stated vehicle or pH. If it does, the § 102 picture for claims 1/2 could change materially — but even then it would need to disclose an alkalizing agent plus an alkaline pH, which the retrieved material does not.
2. Non-patent citations were not the focus of this task (the instruction was "each patent citation"), but for completeness: the listed NPL includes Ruzza et al., Peptides 69 (2015) 26–32 (published 2015-04-03 — § 102(a)(1) art, but it discloses pronetupitant, not a fosnetupitant chloride-hydrochloride alkaline formulation), plus Hesketh 2014 (oral NEPA), Schwartzberg 2018 (IV NEPA Phase 3) and Sun 2015. Per my earlier flag, Schwartzberg 2018 post-dates the 2016-06-06 priority date and is not § 102 art to this patent.
3. Family members are not § 102 art against the '109 patent. US 11,529,362 (16/817,683) and US 10,624,911 (15/611,785) share the same provisional priority (2016-06-06) and are continuations/parents of the '109 patent; they are not available as anticipating references. Likewise, the documents in the "Families Citing this family" table (e.g., US 11,654,154 Navinta; US 12,097,197 Slayback; JP 7783403 Taiho; WO 2025/036703 Helsinn; WO 2025/056094; CN 119185243) post-date the '109 priority date and are not prior art to it.
4. Provenance note. Google Patents lists the citations for this patent in two overlapping tables ("Citations (7)" and "Patent Citations (8)"), with the union being the eight references analysed above; the eighth (WO 2013/082102 A1) is also the reference the '109 specification itself relies on for the method of preparing fosnetupitant. The retrieved table text did not carry reliable examiner/third-party asterisk markers, so I do not purport to assign citation provenance beyond that.

Bottom line: The cited art supports, at most, § 103 challenges (principally WO 2013/082102 alone or in view of WO 2014/005606 and the palonosetron excipient-platform references). No cited reference anticipates any of claims 1–23 under § 102, because no single reference discloses the fosnetupitant chloride hydrochloride salt at 2.3–30 mg/mL together with an alkalizing agent at an alkaline pH (or, for claim 22, the recited NaOH-dissolution → acid-back-titration → excipient-addition sequence).

I'll first ground a few key facts that the prior-art section flagged as unverified — chiefly the formulation/pH disclosure of WO 2013/082102 (the most substantive reference), the '109 prosecution record, and the Pharmathen reference.

Let me pin down what WO 2013/082102 actually discloses regarding formulation, pH, and excipients, and check for parallel art on fosnetupitant salt dissolution chemistry.

Obviousness Analysis — U.S. Patent No. 12,208,109 B2 under 35 U.S.C. § 103

Building on: the Prior-Art section above (which identified the eight examiner-cited patent references and the material NPL). This section does not repeat that reference-by-reference description; it uses it as the evidence base and addresses the legal question the prior-art section expressly reserved — whether the claims would have been obvious.

Verification added in this section: I confirmed by search that (i) the '109 specification's characterization of WO 2013/082102 (IV fosnetupitant at ~10 mg/mL, active-moiety basis) is reproduced verbatim in the family's published counterparts — e.g., CN 109310627 A [0007] (https://patentimages.storage.googleapis.com/55/6a/17/848df2376ff8c1/CN109310627A.pdf#5#1) and BR112018074655B1 (https://patentimages.storage.googleapis.com/b1/29/f3/b79f75533276cc/BR112018074655B1.pdf#5#1); (ii) the '911/'362 family claims and the '109 claims are as reported (https://www.drugpatentwatch.com/p/patent-claims/12208109); and (iii) the granted '109 claim text matches the DrugPatentWatch transcription, including the "sodium chloride" recitations in claims 18/19. I still could not retrieve the full formulation text of WO 2013/082102, and I flag that as the single most important unresolved factual gap — it caps the confidence on the two independent product claims.

No contradiction with prior sections. The 2037-09-18 (Google) vs. 2037-06-02 (DrugPatentWatch) expiry discrepancy persists; it is immaterial to § 103. The D. Del. Cinvanti/aprepitant decision surfaced again (gov.uscourts.ded.79590.180.0.pdf — Heron, aprepitant emulsion patents, priority 2014-09-19); it confirms the prior section's low-confidence characterization and is unrelated to the '109 claims.

---

1. Framework applied

The effective filing date is June 6, 2016 (provisional US 62/345,942; the '109 is a continuation of 16/817,683 ← 15/611,785). Post-AIA, so § 103 is applied through § 102(a)(1) art ("patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date"). All eight cited patent references published 1995–2014 and are therefore § 102(a)(1) art; the AIA common-ownership exception (§ 102(b)(2)(C)) does not reach them because it is limited to § 102(a)(2) art, and the § 102(b)(1)(A) grace period does not reach back ~3 years to Helsinn's own 2013 publications.

The Graham v. John Deere framework governs: scope and content of the prior art; differences between the prior art and the claims; level of ordinary skill; and secondary considerations. KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398 (2007), controls the motivation analysis: the "predictable use of prior art elements according to their established functions," and a "finite number of identified, predictable solutions," defeat patentability even absent an express teaching. MPEP §§ 2141–2144.1 supply the enumerated rationales.

Critical framing point. Claims 1 and 2 are deliberately thin. They do not require netupitant, do not require palonosetron, do not require EDTA or mannitol, and do not require a numeric pH — only "an active ingredient component consisting essentially of from 2.3 to 30 mg/ml of the chloride hydrochloride salt of fosnetupitant," "an alkalizing agent," and "an alkaline pH." That thinness is what makes them vulnerable: the claim monopolizes any alkaline aqueous fosnetupitant chloride-hydrochloride solution in that concentration range. The disclosure that supports them (Example 4) is also the disclosure that supplies the motivation-to-combine language ("New intravenous doses and formulations of fosnetupitant are needed for use in the clinic and commercial distribution").

---

2. Person of ordinary skill in the art (POSHA)

A POSHA here is a formulator with an advanced degree (M.S./Ph.D. in pharmaceutics, pharmaceutical chemistry, or chemical engineering) or a B.S. with 3–5 years of parenteral formulation experience, reasonably working as part of a team that includes an analytical chemist. That person:

• knows that an ionizable API's aqueous solubility is pH-dependent and that the pH of maximum solubility is found empirically;
• knows that a quaternary ammonium/phosphonate-bearing salt (such as the chloride hydrochloride of fosnetupitant) requires a base to dissolve and that pH is subsequently trimmed with acid or base;
• knows the standard parenteral excipient toolkit — chelating agents (disodium edetate), bulking/tonicity agents (mannitol), and NaOH/HCl as pH adjusters — and the standard practice of avoiding buffers where an API is hydrolysis-sensitive;
• reads WO 2013/082102 as the reference source for fosnetupitant and its salts.

This is a formulation-optimization POSHA, not a medicinal chemist. That matters: formulation optimization is the paradigm case of "obvious to try" in a "mature field" (MPEP 2144.03; In re Aller, 220 F.2d 454 (CCPA 1955) — "routine optimization of process conditions").

---

3. The limitations that actually drive the § 103 outcome

One flag carried forward (not auto-corrected): claims 18 and 19 recite "sodium chloride and hydrochloric acid q.s. to pH 7.5–10.0 / 8.5–9.5," whereas the counterpart liquid claim 8 and the entire specification use sodium hydroxide. Read literally, the lyophilized claims 18/19 require NaCl, not NaOH. That literal reading increases their § 103 exposure, because NaCl is itself a standard tonicity-adjusting excipient in lyophilized injectables and its addition to a fosnetupitant powder is routine (see §6-B).

---

4. The § 103 arsenal (from the Prior-Art section)

---

5. Motivation to combine — the enumerated rationales

M1 — Known problem, known need (the applicant's own admission). The '109 specification states that "New intravenous doses and formulations of fosnetupitant are needed for use in the clinic and commercial distribution," and that WO 2013/082102's compound "was developed partly to overcome injection site issues that occurred when its active moiety (netupitant) was administered as the free base." A specification's characterization of the prior art and of the problem to be solved operates as an admission. KSR ("design incentives and other market forces") and MPEP 2144.03 support obviousness of formulating a known drug that the art expressly says needs formulation.

M2 — Expressed motivation to avoid surfactants. The specification states fosnetupitant "takes special additives such as surfactants (e.g. polyoxyethylenesorbitan monooleate)… yet the use of these agents is preferably to be avoided as potentially harmful, in compliance with regulatory safety recommendations." That is a motivation supplied by the applicant's own framing to pursue a surfactant-free aqueous system — i.e., to use pH and standard excipients instead.

M3 — pH adjustment is the known lever for a salt whose solubility is pH-dependent. The '109's own Example 1 records that p-Netu solubility "drops significantly in water at acidic pH values less than 7.0." Once the POSHA knows the molecule is a zwitterionic/quaternary phosphonooxy salt, the choice of an alkaline working pH is the first thing tried, not the last. Under MPEP 2144.03 and Aller, discovering the operable pH window is routine optimization.

M4 — The excipients are the standard parenteral toolkit, disclosed for the same antiemetic space. US 2006/0167072 claims/describes a palonosetron injectable with disodium edetate + mannitol + pH adjustment in a single-use vial. Because Akynzeo® is itself netupitant + palonosetron (300 mg/0.5 mg oral, per the specification), a POSHA formulating an IV fosnetupitant product — and especially an IV fosnetupitant/palonosetron fixed combination — has an express reason to consult the palonosetron injectable art for the second active's excipient architecture. That is the classic KSR "combination of prior-art elements according to known methods to yield predictable results."

M5 — A same-class injectable provides the NaOH/HCl pH-adjuster teaching. WO 2014/005606 is entitled "Stable injectable pharmaceutical composition of neurokinin 1 receptor antagonist" and expressly employs NaOH or HCl to adjust pH. It thereby teaches the POSHA that pH adjustment with these two reagents is the standard technique for injectable NK-1 antagonist products. The "known technique to improve a similar product in the same way" rationale (MPEP 2144.04(b)) applies directly.

M6 — Lyophilization is an expected option. The '109 specification concedes that degradation of the compound is significant and reports the surprising finding that "mother solutions are more stable than the corresponding freeze dried product." A POSHA facing a hydrolysis-prone phosphate-prodrug would contemplate both a liquid and a lyophilized presentation as a matter of routine (dry powder for reconstitution is the standard commercial format for acid-labile parenterals). Claim 2's lyophilized form is therefore an obvious alternative format of the claim 1 composition, and claims 12–19 are its routine parameters.

M7 — The netupitant impurity is a known, characterized consequence. WO 2013/082102's Table 1 degradation data — relied on by the '109 specification itself — plus Ruzza (2015) establish that fosnetupitant hydrolyzes to netupitant. A POSHA who knows the degradation pathway knows the impurity will be present in any aqueous fosnetupitant product and will necessarily bound it. Claims 11/21 (≤2:98) therefore read on the natural, known impurity profile of the prior-art formulation.

M8 — The method is a necessary consequence of the chemistry. Claim 22's sequence (base to dissolve → acid to trim to a still-basic pH → add excipients) is what happens mechanically when one prepares a concentrated aqueous solution of a chloride-hydrochloride double salt at the '109's own values (NaOH to pH ~12 for dissolution; HCl 0.1/1.0 M to 9.00 ± 0.50). Nothing in claim 22 recites an unexpected process parameter: the pH figures in the manufacturing protocol have no numeric limit in claim 22 at all.

---

6. Ground-by-ground analysis

Ground A — Claims 1, 2 (and 3–5, 12–14): WO 2013/082102 in view of US 2006/0167072 and WO 2014/005606

Why the combination is motivated: M1, M3, M4, M5 and M6 above. USP 8,426,450 supplies the compound-and-excipient disclosure, and WO 2013/082102 supplies the IV presentation and concentration. The only elements not expressly shown are "alkalizing agent" and "alkaline pH." Those are supplied by WO 2014/005606 (NaOH as a pH adjuster in a same-class injectable) and independently by simple optimization.

Residual strength of the patent owner's position on claims 1/2: WO 2013/082102's own pH/excipient disclosure is the one thing I could not retrieve. If WO 2013/082102 discloses an acidic or buffered aqueous fosnetupitant formulation — e.g., a phosphate-buffered or pH 4–6 presentation such as the palonosetron art uses — Helsinn will argue that the art pointed away from alkaline and that the alkaline pH was the invention. That argument is only as good as the reference's actual disclosure, and it is answerable via inherency (the '109's own Example 5 demonstrates that NaOH is required to dissolve p-Netu at the target concentration; a prior-art enablement of the same concentration therefore necessarily employs an alkalizing agent). Flagged as unresolved on the present record.

Ground B — Claims 6–9, 15–19 (the excipient package)

This is the strongest § 103 ground in the patent, because it is a near-perfect structural overlap with US 2006/0167072 read with WO 2014/005606:

• Disodium edetate: claimed 0.05–2.0 mg/mL (cl. 7/16) and 0.1–0.9 mg/mL (cl. 8/17/18) overlaps US 2006/0167072's 0.005–1.0 mg/mL EDTA; claim 9's ~0.32 mg/mL and the '109 Example 4's 0.16/0.32 mg/mL fall inside both.
• Mannitol 10–100 mg/mL, ~38 mg/mL: US 2006/0167072 discloses mannitol as the bulking/tonicity agent; 38 mg/mL is an isotonicity-driven value for a 20 mL reconstitution (isotonic mannitol ≈ 5.07% w/v in water; the '109 Tables 4a–4c report ~300–336 mOsm/kg).
• NaOH and HCl q.s. to pH 7.5–10.0: WO 2014/005606 teaches NaOH and HCl for pH adjustment.

Rationale = M4 + M5 + simple substitution of a known element (KSR; MPEP 2144.04(a)). The patent's own Rule 132-type showing that EDTA reduced fosnetupitant→netupitant conversion "in proportion to its concentration" (Example 3) is a dose-response discovery about a known chelator, which strengthens the POSHA's reason to try EDTA (a recognized stabilizer) rather than establishing non-obviousness: the art already taught using EDTA to stabilize an injectable antiemetic.

The "sodium chloride" wrinkle (claims 18, 19, read literally). If those claims are taken at face value, they add NaCl to a lyophilized fosnetupitant powder — the single most routine tonicity agent in lyophilized parenterals and one the specification elsewhere directs to be used (the '109 specification expressly says the reconstituted formulation is compatible with "0.9% NaCl"). The literal reading makes claims 18/19 easier to invalidate, not harder, because the negative limitation "in the absence of a phosphate" (cl. 20) and the NaCl limitation are both satisfied by a conventional saline-compatible lyophilized powder.

Ground C — Claims 10, 20 ("in the absence of a phosphate")

• The base combinations in Grounds A and B are already phosphate-free. A negative limitation that merely excludes something the prior-art combination does not require does not confer patentable weight (In re Gulack; MPEP 2111.01).
• The only cited reference that uses phosphate is WO 2014/005606 (for fosaprepitant). That reference cannot "teach away" from the negative limitation because it is a different drug with a different stability profile, and the POSHA has an independent reason to avoid phosphate (the '109's Example 2 finding that "the presence of buffers, especially phosphates, causes greater hydrolysis" is a general inorganic-chemistry observation about a phosphate-ester prodrug in the presence of competing phosphate species).
• Net effect: claims 10 and 20 are the weakest claims in the patent from a validity standpoint.

Ground D — Claims 11, 21 (netupitant : fosnetupitant 0.01:99.99 to 2:98)

This is the only claim pair with a substantial non-obviousness argument, and it is a narrow one:

• Factual predicate is prior art: WO 2013/082102's Table 1 shows fosnetupitant degrades to netupitant in solution; Ruzza (2015) describes fosnetupitant as the prodrug "pronetupitant" converted to netupitant. So the presence of netupitant in a fosnetupitant formulation is not the invention.
• The applicant's own data define the ceiling: Table 1 shows 1.5–2% netupitant gives a "slightly opalescent solution" and 3% gives a suspension, leading the patent to conclude that "a netupitant concentration of 2.5–3% was determined as the limit for appreciable precipitation." A 2:98 claim ceiling therefore sits below the observed threshold. That is a margin-of-safety limitation, and In re Aller / In re Woodruff treat optimizing a known variable to avoid a known disadvantage as obvious.
• Counter-consideration that helps Helsinn: the same Example 2 also reports that "an initial lower concentration of netupitant does not prevent degradation." If the ratio ceiling is not what prevents degradation, then the ratio is not a "result-effective variable," and one could argue the claim captures no discovered technical effect at all — which hurts the patent differently (written-description/utility), and in a § 103 posture means the ratio is at most a printed-hazard-recital limitation.
• Verdict: claims 11/21 are non-obvious only if Helsinn can show the ≤2:98 ceiling produces a stability/opalescence advantage beyond what the Table 1 data already teach. On the face of the specification, that showing is not made: the specification's own limit (2.5–3%) is higher than the claimed ceiling.

Ground E — Claims 22, 23 (method of manufacture)

Claim 22: (a) admix fosnetupitant salt with NaOH in water at a basic pH; (b) then reduce the pH to a basic pH with an acidic pH-adjusting agent; (c) then admix excipients. Claim 23 limits the acid to HCl.

• No numeric pH is recited in claim 22 — only that both step (a) and step (b) end at "a basic pH." That broadens the claim enormously relative to the specification (which describes step (a) at pH 11–14 and step (b) at 7–10).
• Where taught: WO 2014/005606 (NaOH and HCl for pH adjustment of an injectable NK-1 antagonist formulation); WO 2013/082102 (the fosnetupitant salt presentation to be dissolved); plus basic pharmaceutical practice (MPEP 2144.03; Aller).
• Inherency overlay: the manufacturing sequence of Example 5 (charge NaOH, raise pH to ~13, dissolve p-Netu, trim to 9.00 ± 0.50 with HCl) is the practical necessity of dissolving a chloride-hydrochloride double salt at 13–26 mg/mL. A POSHA following any prior-art instruction to prepare an aqueous fosnetupitant solution at those concentrations would perform steps (a) and (b) mechanically.
• Verdict: claims 22 and 23 are, in my assessment, the most straightforwardly obvious claims in the patent — more so than the product claims, because they omit every numeric limit except the "basic pH" endpoints, and "adjust the pH with NaOH and then back-titrate with HCl" is not an inventive method in any field of parenteral formulation.

---

7. What the patent owner will argue — and how the arguments fare

---

8. Claim-by-claim § 103 risk ranking

Overall: if the WO 2013/082102 formulation text discloses (or inherently requires) an aqueous fosnetupitant presentation with a basic pH adjuster, then claims 1, 2 and 22 fall to a single-reference or two-reference combination, and the entire dependent set falls with them. If it does not, the strongest remaining route to the independent product claims is the three-reference combination WO 2013/082102 + US 2006/0167072 + WO 2014/005606, reinforced by the inherency argument drawn from the applicant's own Example 5.

---

9. Explicit caveats (do not overstate)

1. I did not obtain the full text of WO 2013/082102. Its pH/excipient disclosure is the single fact that decides whether claims 1 and 2 are anticipated (§ 102) or obvious (§ 103). Everything above about the alkaline pH being obvious rather than disclosed rests on that gap. I am not asserting anticipation.
2. These are the references the examiner allowed over. The examiner had the full texts and issued the claims. That is meaningful practical evidence against my Ground A, though it is weaker for Grounds B–E because the examiner's focus (per the family history) was on the "synergy"/method narrative rather than on the parenteral-formulation art.
3. No Rule 132 declaration directed at the '109 formulation claims was retrieved. If one exists in the 17/986,934 file wrapper and is coupled to the alkaline-pH or ratio limitations, the secondary-considerations analysis in §7 would need to be re-weighted.
4. Identifiers were taken literally. The claims 18/19 "sodium chloride" recitations are analyzed as written and not auto-corrected to "sodium hydroxide"; as noted, the literal reading increases their vulnerability. Likewise the DrugPatentWatch claim transcription (https://www.drugpatentwatch.com/p/patent-claims/12208109) matches the granted text, and both were used without correction.
5. Third-party art is not counted here. Post-2016 publications (JP 7783403 B2, WO 2025/036703, WO 2025/056094, CN 119185243 A, US 2024/…/US 2025/0387420 A1) are not § 102/§ 103 prior art against a June 6, 2016 priority date and were excluded from every ground above.

---

10. Bottom line

US 12,208,109 is a formulation-optimization patent in a mature art, drafted so broadly that its two independent product claims recite no more than an alkaline aqueous solution of a fosnetupitant salt in a range the primary prior-art reference already discloses. The claims that carry genuine (but modest) non-obviousness weight are the netupitant-ratio claims 11 and 21, and even those sit beneath a threshold the specification itself supplies (2.5–3% netupitant → opalescence), so the claimed ≤2% ceiling reads as a routine margin rather than a discovered criticality.

The three combinations a challenger should build on are:

• Claims 1–5 and 22–23: WO 2013/082102 (+ US 8,426,450) in view of WO 2014/005606, optionally with US 2006/0167072 — motivated by the acknowledged need for an injectable fosnetupitant product (M1), the acknowledged need to avoid surfactants (M2), and the routine optimization of pH and concentration for an ionizable salt (M3, M8).
• Claims 6–9 and 15–19: WO 2013/082102 + US 2006/0167072 (EDTA + mannitol + single-use vial architecture for an antiemetic injectable that is, per Akynzeo, co-administered with the NK-1 antagonist) + WO 2014/005606 (NaOH/HCl) — a textbook predictable-combination case.
• Claims 10 and 20: collapse for want of patentable weight in the negative limitation.

The one fact that would change this bottom line is the unretrieved content of WO 2013/082102's formulation examples — obtain it, and the analysis either crystallizes into a single-reference case or hardens into a two-to-three-reference obviousness case.